Vera Constâncio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3904394/publications.pdf

Version: 2024-02-01

687363 713466 21 485 13 21 citations h-index g-index papers 22 22 22 731 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. Cellular Oncology (Dordrecht), 2022, 45, 135-149.	4.4	2
2	LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma. Cancers, 2022, 14, 858.	3.7	15
3	One sample fits all: a microfluidic-assisted methodology for label-free isolation of CTCs with downstream methylation analysis of cfDNA in lung cancer. Biomaterials Science, 2022, 10, 3296-3308.	5.4	2
4	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Communications Biology, 2021, 4, 119.	4.4	18
5	Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. ESMO Open, 2021, 6, 100039.	4.5	22
6	Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. Cancers, 2021, 13, 1529.	3.7	21
7	Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Molecular Oncology, 2021, 15, 846-865.	4.6	15
8	Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples. Clinical Epigenetics, 2021, 13, 70.	4.1	13
9	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers, 2021, 13, 2848.	3.7	14
10	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. Journal of Personalized Medicine, 2021, 11, 996.	2.5	20
11	Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma. Cancers, 2021, 13, 5252.	3.7	8
12	Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7427.	4.1	24
13	Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer. Journal of Clinical Medicine, 2020, 9, 3911.	2.4	5
14	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone $na\tilde{A}$ -ve prostate cancer. Prostate, 2020, 80, 1353-1364.	2.3	4
15	DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. Cells, 2020, 9, 624.	4.1	108
16	Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. Frontiers in Oncology, 2019, 9, 900.	2.8	69
17	Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies. Journal of Clinical Medicine, 2019, 8, 1500.	2.4	37
18	Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies. Expert Review of Molecular Diagnostics, 2019, 19, 367-375.	3.1	10

Vera Constâncio

#	Article	IF	CITATIONS
19	Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clinical Epigenetics, 2019, 11, 175.	4.1	40
20	PROSTAGLANDIN E ₂ stimulates cancerâ€related phenotypes in prostate cancer PC3 cells through cyclooxygenaseâ€2. Journal of Cellular Physiology, 2019, 234, 7548-7559.	4.1	17
21	Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clinical Epigenetics, 2018, 10, 132.	4.1	21